Delmadinone acetate
Progestin; Progestogen ester; Steroidal antiandrogen | |
ATCvet code | ) |
---|---|
Identifiers | |
| |
JSmol) | |
| |
|
Delmadinone acetate (DMA), sold under the brand name Tardak among others, is a
Uses
Veterinary
DMA is used to treat androgen-dependent conditions in animals.[6] It is most commonly used to treat benign prostatic hyperplasia.[6] However, it can also be used to treat hypersexuality in male dogs and cats, perianal gland tumors in dogs, and hormone-driven aggression in dogs.[6]
Pharmacology
Pharmacodynamics
DMA is a
Chemistry
DMA, also known as 1-dehydrochlormadinone acetate, as well as 1,6-didehydro-6-chloro-17α-acetoxyprogesterone or '6-chloro-17α-hydroxypregna-1,4,6-triene-3,20-dione, is a
History
DMA was first described in the literature in 1959 and has been marketed since at least 1972.[1][8][9] It was marketed by this year in Europe and the United Kingdom under the brand names Tardak and Zenadrex.[9] It was under development for use in the United States as well but does not seem to have ultimately been marketed in this country.[9]
Society and culture
Generic names
Delmadinone acetate is the
andBrand names
DMA is most commonly sold as Tardak, but has also been marketed under a variety of other brand names including Delmate, Estrex, Tardastren, Tardastrex, Vetadinon, and Zenadrex.[1][2][4]
Availability
DMA is available in Europe and Oceania.[2][4] It is specifically marketed in the United Kingdom, France, Belgium, Germany, Austria, Switzerland, the Netherlands, Finland, Australia, and New Zealand.[2][4]
References
- ^ ISBN 978-1-4757-2085-3.
- ^ ISBN 978-3-88763-075-1. Retrieved 30 May 2012.
- ^ ISBN 978-0-7514-0499-9. Retrieved 30 May 2012.
- ^ a b c d e f g "List of Progestins". Drugs.com.
- PMID 9741725.
- ^ ISSN 1464-4630.
- S2CID 5612000.
- ISSN 0002-7863.
- ^ a b c Modern Veterinary Practice. Vol. 53. 1972. p. 46.
John T. Bryans, University of Kentucky, Lexington. Thoroughbred Record 194(22): 1634-1636, 1971. In the clinical review entitled "Antiandrogen Treatment of Prostate Disorders" (MVP Oct, p 46} the product should have been identified as delta-chlor- madinone acetate (delta-CAP, rather than as CAP). This compound, also known as delmadinone acetate, has unique properties and is marketed in Europe and the UK as Tardak® and Zenadrex®; It is presently subject to clinical investigation in the US for FDA approval.